Viridian Therapeutics, Inc.\DE
VRDN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VRDN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, with a pipeline targeting autoimmune and rare disease pathways including IGF-1R, FcRn, and TSHR.
Key risk: History of losses and need for capital
BioSniper Score
Based on 6 of 6 signals
Market Cap
$2.61B
Cash Runway
27.6 moLead Asset
elegrobart (Phase 3)
Next Catalyst
Phase3_Topline · Oct 1, 2026Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 8 clinical trials · 3 catalysts for Viridian Therapeutics, Inc.\DE.
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, with a pipeline targeting autoimmune and rare disease pathways including IGF-1R, FcRn, and TSHR.
- Viridian Therapeutics is a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases [sec · filed 2025-04-25].
- The company targets disease areas where marketed therapies leave room for improvements in efficacy, safety, and/or dosing convenience [sec_mda · as of 2026-02-26].
- As of June 30, 2026, Viridian reported cash and equivalents of $165.0M, total revenue of $0.3M, and a net loss of -$127.1M [latest reported financials].
- The company expects its cash, cash equivalents, and marketable securities of $981.5 million as of June 30, 2026 will fund planned operations for at least twelve months [sec_mda · as of 2026-08-06].
- Viridian's pipeline includes product candidates directed at IGF-1R for thyroid eye disease (TED), FcRn inhibitors for autoimmune disorders, and a TSHR inhibitor program [sec_mda · as of 2026-02-26].
What works
- Viridian targets validated pathways (IGF-1R, FcRn, TSHR) with potential for best-in-class differentiation in efficacy, safety, or dosing convenience [sec_mda · as of 2026-02-26].
- The company has a strong cash position of $981.5 million as of June 30, 2026, providing a runway of at least twelve months to fund operations and clinical trials [sec_mda · as of 2026-08-06].
- Viridian's strategy of improving upon first-generation therapies in rare diseases may allow for efficient development and reduced risk [sec · filed 2026-04-17].
What to weigh
- Viridian has incurred significant losses, with a net loss of -$127.1M for the six months ended June 30, 2026, and expects to continue incurring losses for the foreseeable future [latest reported financials; sec_mda · as of 2026-05-05].
- The company will require additional capital to continue financing operations, and its ability to secure funding is subject to various risks [sec_mda · as of 2025-08-06].
- Clinical trials are costly, time-consuming, and inherently risky; Viridian may fail to demonstrate safety and efficacy to regulatory satisfaction [sec_mda · as of 2026-05-05].
From the filings
Quoted directly from source documents.
Viridian focuses on best-in-class medicines for serious and rare diseases.
“We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases.”
SEC filings · April 25, 2025
Viridian targets areas where current treatments have room for improvement.
“We target disease areas where marketed therapies often leave room for improvements in efficacy, safety, and/or dosing convenience.”
SEC filings · February 26, 2026
Viridian expects to fund operations for at least twelve months from June 30, 2026.
“The Company expects that its cash, cash equivalents and marketable securities as of June 30, 2026 of $ 981.5 million will enable the Company to fund its planned operations for at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements.”
SEC MD&A · August 6, 2026
Viridian's pipeline includes IGF-1R, FcRn, and TSHR programs.
“These include product candidates directed at the IGF‑1R for the treatment of TED, inhibitors of the FcRn with potential application across multiple autoimmune disorders, and a TSHR inhibitor program with potential in”
SEC MD&A · February 26, 2026
Catalyst timeline
- 2026-10-01 · Phase3_Topline · vrdn-003 — Phase 3 Topline: A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants W — Topline safety and tolerability data from a Phase 3 study of VRDN-003 in thyroid eye disease will be reported.
- 2026-11-15 · Phase3_Topline · vrdn-003 — Phase 3 Topline: REVEAL-1 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerabil — Topline efficacy and safety data from the REVEAL-1 Phase 3 trial of VRDN-003 will be released.
- 2026-12-15 · Phase3_Topline · vrdn-003 — Phase 3 Topline: REVEAL-2 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerabil — Topline efficacy and safety data from the REVEAL-2 Phase 3 trial of VRDN-003 will be released.
Risks & what to watch (3)›
Key risks
- History of losses and need for capital — Viridian has incurred significant losses and expects to continue doing so; it will need additional capital to fund operations [latest reported financials; sec_mda · as of 2026-05-05].
- Clinical trial and regulatory risks — Clinical trials are costly and risky; failure to demonstrate safety/efficacy could delay or prevent approval [sec_mda · as of 2026-05-05].
- Dependence on pipeline success — Viridian's future depends on successful development and commercialization of its product candidates, which are in early-to-mid stages [sec_mda · as of 2026-02-26].
What to watch
- Topline data from Phase 3 trials of VRDN-003 for thyroid eye disease, expected in late 2026 [upcoming catalysts].
- Viridian's ability to secure additional capital to extend its cash runway beyond the current twelve-month horizon [sec_mda · as of 2025-08-06].
- Progress of the FcRn inhibitor and TSHR inhibitor programs through preclinical and clinical development [sec_mda · as of 2026-02-26].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Viridian Therapeutics, Inc.\DE through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Viridian Therapeutics, Inc.\DE facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
27.6 months
D/E 0.66
Lead: Phase 3
3 candidates
3 upcoming, next in ~32d
1 buy · 2 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
222
Total value held
$1.93B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 15,379,377 | $300.8M |
| vanguard capital management llc | 8,334,402 | $163.0M |
| blackrock, inc. | 7,831,475 | $153.2M |
| state street corp | 4,672,885 | $91.4M |
| wellington management group llp | 3,078,554 | $60.2M |
| citadel advisors llc | 2,382,934 | $46.6M |
| perceptive advisors llc | 2,341,658 | $45.8M |
| kynam capital management, lp | 2,341,652 | $45.8M |
| geode capital management, llc | 2,333,213 | $45.6M |
| balyasny asset management l.p. | 2,315,957 | $45.3M |
Showing top 10 of 222 institutional holders of Viridian Therapeutics, Inc.\DE. Open the full 13F history after sign-in.
Short Interest
as of Apr 22, 2026- % of float
- 11.0%
- Days to cover
- 5.3
- Shares short
- 10,843,213
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VRDN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Viridian Therapeutics, Inc.\DE?
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, with a pipeline targeting autoimmune and rare disease pathways including IGF-1R, FcRn, and TSHR.
What is Viridian Therapeutics, Inc.\DE's lead drug candidate?
Viridian Therapeutics, Inc.\DE's most advanced tracked candidate is elegrobart (Phase 3) for Thyroid Eye Disease (TED) - active and chronic.
What is Viridian Therapeutics, Inc.\DE's next catalyst?
Viridian Therapeutics, Inc.\DE's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants W" — expected October 1, 2026.
Who is the CEO of Viridian Therapeutics, Inc.\DE?
Mr. Stephen F. Mahoney J.D., MBA is the chief executive officer of Viridian Therapeutics, Inc.\DE (VRDN).
Where is Viridian Therapeutics, Inc.\DE headquartered?
Viridian Therapeutics, Inc.\DE (VRDN) is headquartered in Waltham, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.